Skip to content

Immunogenetic characteristics of spleen deficiency in chronic gastritis and its effect on the therapeutic response to Yiqi and Spleen strengthening therapy

Construction of a predictive model based on immunomolecular typing for the diagnosis of spleen deficiency syndrome in chronic gastritis and the therapeutic response of the method of benefiting qi and strengthening the spleen

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2024000337
Enrollment
Unknown
Registered
2024-08-31
Start date
2024-09-06
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic gastritis

Interventions

Spleen Deficiency Group:Conventional treatment, given to benefit qi and strengthen the spleen method of Chinese medicine Xiangsha Liu Junzi Tang plus flavor intervention
Non-Spleen Deficiency Group:Record the details of the medication received by the patient and follow up the patients clinical performance before and after taking the medication etc.

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Western medical diagnosis is in accordance with the diagnostic criteria for chronic gastritis in the "China Chronic Gastritis Diagnosis and Treatment Guidelines (2022, Shanghai)"; 2. Chinese medicine diagnosis is in accordance with the diagnostic criteria of Chinese medicine diagnosis of chronic gastritis in the Expert Consensus on Chinese Medicine Diagnosis and Treatment of Chronic Gastritis (2023, Shanghai); 3. The patient's age is over 18 years old; 4. The patient gives informed consent and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with primary heart, liver, lung, kidney, blood diseases or other serious pathologies; 2. patients during pregnancy, perinatal period, lactation, perioperative period; 3. patients with history of gastrointestinal surgery; 4. history of tumours in the digestive tract; 5. combined malignant tumours of other systems or organs.

Design outcomes

Primary

MeasureTime frame
Clinical response rates based on core dyspepsia symptom scores at week 8;

Secondary

MeasureTime frame
SDS;Gastroscopy and pathological findings;SAS;pepsinogen;Clinical response rates for the eight weekly dyspepsia symptom scores;Quality of Life Short Form 12;Helicobacter pylori eradication rate;Quantitative grading score for the main symptoms of spleen deficiency syndrome;

Countries

China

Contacts

Public ContactZhong Zishao

Guangdong Provincial Hospital of Chinese Medicine

zhongzishao@gzucm.edu.cn81887233-63422

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026